Loading...
|
Please use this identifier to cite or link to this item:
http://ir.nhri.org.tw/handle/3990099045/16231
|
| Title: | Comparative risk of neuropsychiatric adverse events associated with leukotriene-receptor antagonists versus inhaled corticosteroids |
| Authors: | Yao, TC;Huang, JL;Wu, CS;Horng-Shing Lu, H;Chang, YC;Chen, WY;Kao, HF;Wu, AC;Tsai, HJ |
| Contributors: | National Center for Geriatrics and Welfare Research;Institute of Population Health Sciences |
| Abstract: | BACKGROUND: Leukotriene-receptor antagonists (LTRA) and inhaled corticosteroids (ICS) are common controller medications for asthma, but limited studies examine their comparative risks on neuropsychiatric adverse events (NAEs) in patients with asthma. OBJECTIVE: To investigate the comparative risks of LTRA versus ICS on 7 distinct categories of NAEs in patients with asthma at a nationwide level. METHODS: We conducted a nationwide cohort study during 2010-2021. Incident NAEs and their clinical subgroups (eg, psychotic disorders, anxiety disorders, movement disorders, behavioral and emotional disorders, mood disorders, sleep-related disorders, and personality disorders) were assessed. Cox proportional hazards regressions were used to quantify the comparative risks. RESULTS: There were 1,249,897 patients with asthma aged 6 to 64 years. Incidence rates for NAEs were 25.10 per 1000 person-years among patients treated with LTRA and 23.46 per 1000 person-years among those treated with ICS. The incidence rate difference was 1.64 (95% confidence interval [CI]: 0.30-2.98) per 1000 person-years. Positive associations of NAEs and 3 clinical subgroups were found in patients treated with LTRA compared with ICS (hazard ratios [HR]: 1.06 [95% CI: 1.00-1.12] for NAEs; HR: 1.88 [95% CI: 1.24-2.84] for psychotic disorders; HR: 1.10 [95% CI: 1.01-1.20] for anxiety disorders; and HR: 1.27 [95% CI: 1.02-1.58] for behavioral and emotional disorders), but not for movement disorders, mood disorders, sleep-related disorders, and personality disorders. CONCLUSIONS: This nationwide cohort study identified heightened risks, ranging from 6% to 88%, of NAEs and 3 clinical subgroups in patients with asthma treated with LTRA compared with ICS. These findings underscore the necessity for clinicians to communicate with patients regarding potential neuropsychiatric harms when prescribing LTRA. |
| Date: | 2024-10-04 |
| Relation: | Journal of Allergy and Clinical Immunology. In Practice. 2024 Oct 04;Article in Press. |
| Link to: | http://dx.doi.org/10.1016/j.jaip.2024.09.028 |
| JIF/Ranking 2023: | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=2213-2198&DestApp=IC2JCR |
| Appears in Collections: | [吳其炘] 期刊論文
[蔡慧如] 期刊論文
|
Files in This Item:
| File |
Description |
Size | Format | |
|---|
| PUB39369853.pdf | | 869Kb | Adobe PDF | 15 | View/Open |
|
All items in NHRI are protected by copyright, with all rights reserved.
|
